Which has higher valuation and earnings, CVKD or MBRX?

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadrenal Therapeutics N/A N/A -$13.24M -$4.90 N/A Moleculin Biotech N/A N/A -$33.56M -$7.13 N/A

Is CVKD or MBRX more profitable?

Moleculin Biotech's return on equity of -143.51% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cadrenal Therapeutics N/A -406.41% -273.80% Moleculin Biotech N/A -143.51% -24.53%

Does the media prefer CVKD or MBRX?

In the previous week, Cadrenal Therapeutics and Cadrenal Therapeutics both had 2 articles in the media. Cadrenal Therapeutics' average media sentiment score of 0.99 beat Moleculin Biotech's score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadrenal Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, CVKD or PSTV?

Plus Therapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadrenal Therapeutics N/A N/A -$13.24M -$4.90 N/A Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A

Does the media favor CVKD or PSTV?

In the previous week, Cadrenal Therapeutics had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 1 mentions for Plus Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.99 beat Plus Therapeutics' score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadrenal Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CVKD or SCNX more profitable?

Scienture's return on equity of -53.51% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cadrenal Therapeutics N/A -406.41% -273.80% Scienture N/A -53.51% -42.47%

Does the media favor CVKD or SCNX?

In the previous week, Scienture had 1 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 3 mentions for Scienture and 2 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.99 beat Scienture's score of 0.06 indicating that Cadrenal Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadrenal Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scienture 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, CVKD or QNRX?

Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadrenal Therapeutics N/A N/A -$13.24M -$4.90 N/A Quoin Pharmaceuticals N/A N/A -$15.81M -$25.18 N/A

Is CVKD or QNRX more profitable?

Cadrenal Therapeutics' return on equity of -406.41% beat Quoin Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Cadrenal Therapeutics N/A -406.41% -273.80% Quoin Pharmaceuticals N/A -489.57% -221.17%

Does the media refer more to CVKD or QNRX?

In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 2 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.99 beat Quoin Pharmaceuticals' score of 0.25 indicating that Cadrenal Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadrenal Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cadrenal Therapeutics (CVKD) Competitors

$1.26 -0.06 (-4.17%)

As of 09:45 AM Eastern

Compare

CVKD vs. MBRX, PSTV, DARE, SCNX, and QNRX

Should you buy Cadrenal Therapeutics stock or one of its competitors? Cadrenal Therapeutics's main competitors and comparable companies include Moleculin Biotech (MBRX), Plus Therapeutics (PSTV), Dare Bioscience (DARE), Scienture (SCNX), and Quoin Pharmaceuticals (QNRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cadrenal Therapeutics compare to Moleculin Biotech?

Cadrenal Therapeutics (NASDAQ:CVKD) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 14.6% of Cadrenal Therapeutics shares are held by company insiders. Comparatively, 18.0% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cadrenal Therapeutics and Cadrenal Therapeutics both had 2 articles in the media. Cadrenal Therapeutics' average media sentiment score of 0.99 beat Moleculin Biotech's score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadrenal Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Moleculin Biotech's return on equity of -143.51% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-406.41%	-273.80%
Moleculin Biotech	N/A	-143.51%	-24.53%

Cadrenal Therapeutics currently has a consensus target price of $13.00, indicating a potential upside of 927.67%. Moleculin Biotech has a consensus target price of $3.00, indicating a potential upside of 479.15%. Given Cadrenal Therapeutics' higher probable upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Moleculin Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cadrenal Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

Summary

Moleculin Biotech beats Cadrenal Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Plus Therapeutics?

Cadrenal Therapeutics (NASDAQ:CVKD) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Plus Therapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

Cadrenal Therapeutics has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-406.41%	-273.80%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Cadrenal Therapeutics presently has a consensus price target of $13.00, indicating a potential upside of 927.67%. Plus Therapeutics has a consensus price target of $51.75, indicating a potential upside of 2,449.26%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 14.6% of Cadrenal Therapeutics shares are held by insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cadrenal Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

In the previous week, Cadrenal Therapeutics had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 1 mentions for Plus Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.99 beat Plus Therapeutics' score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadrenal Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cadrenal Therapeutics beats Plus Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Dare Bioscience presently has a consensus target price of $6.50, suggesting a potential upside of 706.45%. Cadrenal Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 927.67%. Given Cadrenal Therapeutics' higher possible upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Dare Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cadrenal Therapeutics had 2 more articles in the media than Dare Bioscience. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 0 mentions for Dare Bioscience. Cadrenal Therapeutics' average media sentiment score of 0.99 beat Dare Bioscience's score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Dare Bioscience	Neutral
Cadrenal Therapeutics	Positive

Dare Bioscience has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market.

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 4.1% of Dare Bioscience shares are owned by company insiders. Comparatively, 14.6% of Cadrenal Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cadrenal Therapeutics has lower revenue, but higher earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	15.39	-$13.40M	-$0.70	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A

Cadrenal Therapeutics has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Cadrenal Therapeutics' return on equity of -406.41% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-748.30%	-38.75%
Cadrenal Therapeutics	N/A	-406.41%	-273.80%

Summary

Cadrenal Therapeutics beats Dare Bioscience on 10 of the 15 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Scienture?

Cadrenal Therapeutics (NASDAQ:CVKD) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Scienture shares are owned by institutional investors. 14.6% of Cadrenal Therapeutics shares are owned by company insiders. Comparatively, 21.4% of Scienture shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Scienture's return on equity of -53.51% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-406.41%	-273.80%
Scienture	N/A	-53.51%	-42.47%

Cadrenal Therapeutics has higher earnings, but lower revenue than Scienture. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A
Scienture	$430K	26.74	-$41.51M	-$2.10	N/A

Cadrenal Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market. Comparatively, Scienture has a beta of 3.25, suggesting that its stock price is 225% more volatile than the broader market.

In the previous week, Scienture had 1 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 3 mentions for Scienture and 2 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.99 beat Scienture's score of 0.06 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadrenal Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scienture	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cadrenal Therapeutics presently has a consensus price target of $13.00, indicating a potential upside of 927.67%. Scienture has a consensus price target of $1.50, indicating a potential upside of 435.71%. Given Cadrenal Therapeutics' higher probable upside, research analysts plainly believe Cadrenal Therapeutics is more favorable than Scienture.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Scienture beats Cadrenal Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Quoin Pharmaceuticals?

Cadrenal Therapeutics (NASDAQ:CVKD) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 2 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.99 beat Quoin Pharmaceuticals' score of 0.25 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadrenal Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cadrenal Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market.

Cadrenal Therapeutics currently has a consensus target price of $13.00, indicating a potential upside of 927.67%. Quoin Pharmaceuticals has a consensus target price of $20.00, indicating a potential upside of 187.77%. Given Cadrenal Therapeutics' higher possible upside, research analysts plainly believe Cadrenal Therapeutics is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cadrenal Therapeutics' return on equity of -406.41% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-406.41%	-273.80%
Quoin Pharmaceuticals	N/A	-489.57%	-221.17%

Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$25.18	N/A

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 14.6% of Cadrenal Therapeutics shares are owned by insiders. Comparatively, 11.2% of Quoin Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Cadrenal Therapeutics beats Quoin Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Cadrenal Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVKD vs. The Competition

Export

Metric	Cadrenal Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.59M	$12.59B	$7.31B	$13.28B
Dividend Yield	N/A	2.63%	2.52%	12.56%
P/E Ratio	-0.26	792.28	274.07	25.70
Price / Sales	N/A	857.34	673.22	90.62
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	1.08	10.58	10.38	6.32
Net Income	-$13.24M	$2.81B	$3.49B	$359.73M
7 Day Performance	12.95%	-0.16%	-0.69%	0.17%
1 Month Performance	-19.43%	-1.38%	-3.19%	-3.27%
1 Year Performance	-90.82%	2.83%	15.12%	5.58%

Cadrenal Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVKD Cadrenal Therapeutics	2.6836 of 5 stars	$1.27 -4.2%	$13.00 +927.7%	-90.4%	$4.59M	N/A	N/A	5
MBRX Moleculin Biotech	3.0936 of 5 stars	$0.75 -3.0%	$3.00 +299.1%	-95.1%	$15.10M	N/A	N/A	20	News Coverage Gap Up
PSTV Plus Therapeutics	1.3019 of 5 stars	$2.17 -6.7%	$51.75 +2,284.8%	-79.9%	$14.94M	N/A	N/A	20
DARE Dare Bioscience	2.4216 of 5 stars	$0.73 -0.8%	$6.50 +790.3%	-60.8%	$14.48M	$1.03M	N/A	30
SCNX Scienture	2.9535 of 5 stars	$0.33 -2.2%	$1.50 +352.5%	-66.3%	$13.92M	$430K	N/A	N/A	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVKD) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cadrenal Therapeutics (CVKD) Competitors

CVKD vs. MBRX, PSTV, DARE, SCNX, and QNRX

How does Cadrenal Therapeutics compare to Moleculin Biotech?

Summary

How does Cadrenal Therapeutics compare to Plus Therapeutics?

Summary

How does Cadrenal Therapeutics compare to Dare Bioscience?

Summary

How does Cadrenal Therapeutics compare to Scienture?

Summary

How does Cadrenal Therapeutics compare to Quoin Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD vs. The Competition

Cadrenal Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cadrenal Therapeutics (CVKD) Competitors

CVKD vs. MBRX, PSTV, DARE, SCNX, and QNRX

How does Cadrenal Therapeutics compare to Moleculin Biotech?

Do insiders and institutionals hold more shares of CVKD or MBRX?

Does the media prefer CVKD or MBRX?

Is CVKD or MBRX more profitable?

Do analysts recommend CVKD or MBRX?

Which has more volatility and risk, CVKD or MBRX?

Which has higher valuation and earnings, CVKD or MBRX?

Summary

How does Cadrenal Therapeutics compare to Plus Therapeutics?

Which has higher valuation and earnings, CVKD or PSTV?

Is CVKD or PSTV more profitable?

Do analysts prefer CVKD or PSTV?

Do institutionals and insiders hold more shares of CVKD or PSTV?

Which has more risk & volatility, CVKD or PSTV?

Does the media favor CVKD or PSTV?

Summary

How does Cadrenal Therapeutics compare to Dare Bioscience?

Do analysts prefer DARE or CVKD?

Does the media prefer DARE or CVKD?

Which has more volatility & risk, DARE or CVKD?

Do insiders and institutionals have more ownership in DARE or CVKD?

Which has better valuation and earnings, DARE or CVKD?

Is DARE or CVKD more profitable?

Summary

How does Cadrenal Therapeutics compare to Scienture?

Do insiders & institutionals believe in CVKD or SCNX?

Is CVKD or SCNX more profitable?

Which has stronger earnings & valuation, CVKD or SCNX?

Which has more risk and volatility, CVKD or SCNX?

Does the media favor CVKD or SCNX?

Do analysts rate CVKD or SCNX?

Summary

How does Cadrenal Therapeutics compare to Quoin Pharmaceuticals?

Does the media refer more to CVKD or QNRX?

Which has more volatility and risk, CVKD or QNRX?

Do analysts rate CVKD or QNRX?

Is CVKD or QNRX more profitable?

Which has preferable valuation and earnings, CVKD or QNRX?

Do insiders & institutionals have more ownership in CVKD or QNRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD vs. The Competition

Cadrenal Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools